Federal Register / Vol. 69, No. 189 / Thursday, September 30, 2004 / Notices 58541

(2004); Anne Lazar Thorn, M.D., 62 FR 

847 (1997). 

Here, it is clear Dr. Edwin is not 

currently licensed to handle controlled 

substances in Illinois, where he is 

registered with DEA. Therefore, he is 

not entitled to maintain that 

registration. Because Dr. Edwin is not 

entitled to a DEA registration in Illinois 

due to lack of state authorization to 

handle controlled substances, the 

Deputy Administrator concludes it is 

unnecessary to address whether Dr. 

Edwin’s registration should be revoked 

based upon the remaining public 

interest grounds asserted in the Order to 

Show Cause/Immediate Suspension of 

Registration. See Fereida WalkerGraham, M.D., 68 FR 24761 (2003); 

Nathaniel-Aikens-Afful, M.D., 69 FR 

16871 (1997); Sam F. Moore, D.V.M., 58 

FR 14428 (1993). 

Accordingly, the Deputy 

Administrator of the Drug Enforcement 

Administration, pursuant to the 

authority vested in her by 21 U.S.C. 823 

and 824 and 28 CFR 0.100(b) and 0.104, 

hereby orders that DEA Certificate of 

Registration, AE7528295, issued to 

Paramabaloth Edwin, M.D., be, and it 

hereby is, revoked. The Deputy 

Administrator further orders that any 

pending applications for renewal or 

modification of such registration be, and 

they hereby are, denied. This order is 

effective November 1, 2004.

Dated: September 13, 2004. 

Michele M. Leonhart, 

Deputy Administrator.

[FR Doc. 04–21967 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to 21 CFR 1301.33(a), this is 

a notice that on June 10, 2004 Aldrich 

Chemical Company Inc., DBA Isotec, 

3858 Benner Road, Miamisburg, Ohio 

45342–4304, made application by 

renewal to the Drug Enforcement 

Administration (DEA) for registration as 

a bulk manufacturer of the basic classes 

of controlled substances listed:

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

N-Ethylamphetamine (1475) ........ I 

N,N-Dimethylamphetamine (1480) I 

Aminorex (1585) ........................... I 

Gamma hydroxybutyric acid 

(2010).

I 

Methaqualone (2565) ................... I 

Drug Schedule 

Lysergic acid dethylamide (7315) I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

2,5-Dimethoxyamophetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4-Methylenedioxy-methamphetamine (7405).I 

4-Methoxyamphetamine (7411) ... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

N-Ethyl-1-phenylcyclohexalamine 

(7455).

I 

Dihydromorphine (9145) ............... I 

Normorphine (9313) ..................... I 

Acetylmethadol (9601) ................. I 

Alphacetylmethadol Except LevoAlphacetylmethadol (9603).I 

Normethadone (9635) .................. I 

3-Methylfentanyl (9813) ................ I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

1-Phenylcyclohexalamine (7460) II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

1-Piperidinocyclohexanecarbonitrile (8603).II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Isomethadone (9226) ................... II 

Meperidine (9230) ........................ II 

Meperidine intermediate-A (9232) II 

Meperidine intermediate-B (9233) II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Dextropropoxyphene, bulk, (nondosage forms) (9273).II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

small quantities of the listed controlled 

substances to produce isotope labeled 

standards for drug analysis. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, United 

States Department of Justice, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative (CCD) 

and must be filed no later than (60 days 

from publication).

Dated: September 16, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–21944 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Sheldon Kantor, D.P.M.; Revocation of 

Registration 

On March 28, 2003, the then-Acting 

Administrator of the Drug Enforcement 

Administration (DEA) issued an Order 

to Show Cause/Immediate Suspension 

of Registration to Sheldon Kantor, 

D.P.M. (Dr. Kantor) of Hollywood, 

Florida. Dr. Kantor was notified of an 

opportunity to show cause as to why 

DEA should not revoke his DEA 

Certificate of Registration, AK4080545, 

as a practitioner, and deny any pending 

applications for renewal or modification 

of such registration pursuant to 21 

U.S.C. 823(f) and 824(a) for reason that 

his continued registration would be 

inconsistent with the public interest. Dr. 

Kantor was further notified that his DEA 

registration was immediately suspended 

as an imminent danger to the public 

health and safety pursuant to 21 U.S.C. 

824(d). 

The Order to Show Cause/Immediate 

Suspension alleged in relevant part, that 

during the week of February 24, 2003, 

and again on March 3, 2003, DEA 

received information from a registered 

distributor of controlled substances that 

Dr. Kantor had ordered and received 

large quantities of Schedule III and IV 

controlled substances. In response, DEA 

investigators presented Dr. Kantor with 

a Notice of Inspection, however, he 

refused to consent to the inspection. 

While speaking with investigators, Dr. 

Kantor admitted he had not maintained 

a log of controlled substances 

dispensed. When an investigator 

inquired as to the location of previously 

received controlled substances, Dr. 

Kantor stated that they were in the trunk 

of his car. He then refused to disclose 

the whereabouts of that vehicle. The 

Order to Show Cause alleged that Dr. 

Kantor also refused to consent to a 

subsequent inspection of his registered 

location. 

The Order to Show Cause alleged that 

Dr. Kantor had been convicted in federal 

court and sentenced to 21 months 

imprisonment, commencing March 23, 

2003, for his involvement in a scheme